AVANOS MEDICAL, INC. 8-K

What Happened
Avanos Medical, Inc. announced it entered into a definitive Merger Agreement under which A-AV MergerSub will merge into Avanos, leaving Avanos as a wholly owned subsidiary of A-AV Holdco I. The company filed a definitive proxy on June 10, 2026 for a special stockholder meeting on July 22, 2026 to vote on the merger and related proposals. Avanos says the merger consideration is $25.00 per share and that the board unanimously recommends stockholders vote “FOR” the merger, the advisory compensation proposal and the adjournment proposal.

Avanos also disclosed two shareholder lawsuits filed June 29–30, 2026 in New York Supreme Court seeking to enjoin the merger and alleging disclosure deficiencies, plus demand letters from other purported stockholders. Avanos disputes the claims but is voluntarily supplementing its definitive proxy to address the asserted disclosure issues and avoid delay or litigation costs; the supplements do not change the merger terms or meeting timing.

Key Details

• Special meeting set for July 22, 2026; definitive proxy filed June 10, 2026.
• Merger consideration: $25.00 per share; Avanos’ board unanimously recommends approval.
• Lawsuits: Williams v. Avanos Medical, Inc. (No. 653829/2026) and Stevens v. Avanos Medical, Inc. (No. 653863/2026) filed June 29–30, 2026 (NY Supreme Court, New York County); plaintiffs seek injunction and fees.
• Supplemental disclosures added to the proxy include: UBS conflict/revenue disclosure and an estimated UBS fee of up to $5 million upon closing; confirmation that AIP did not discuss executive terminations prior to signing; JP Morgan valuation analyses (public multiples range 7.0x–12.6x, median 9.4x; selected transactions range 6.3x–13.4x, median 10.7x) and implied per‑share equity value ranges that JP Morgan compared to the $25.00 merger price; forecasted Adjusted EBITDA (including SBC) for the 12 months ending March 31, 2026 of $82.4 million (calculation: FY2025 actual $86.8M − Q1 2025 $21.6M + Q1 2026 forecast $17.2M).
• Forecasts do not reflect post‑preparation events, synergies or the merger’s effects; Avanos disclaims any obligation to update forecasts except as required by law.

Why It Matters
This filing confirms a definitive $25.00/share buyout and the timetable for shareholder approval, while also signaling procedural risk: shareholder litigation and demand letters allege disclosure deficiencies that the company chose to address via supplemental proxy disclosures. For retail investors, the key takeaways are the fixed cash/consideration per share ($25.00), the July 22, 2026 vote date, the board’s unanimous recommendation, and the potential for litigation to delay or complicate closing (Avanos is seeking to minimize that risk by supplementing disclosures). The supplemental items provide more detail on advisor fees, valuation analyses and the company’s forecasts—useful context when weighing the merger price versus recent trading levels and valuation metrics.